低强度冲击波治疗经尿道手术治疗良性前列腺梗阻后持续储尿症状的随机对照试验
该随机对照试验将137例经尿道手术治疗良性前列腺梗阻后持续储尿症状至少三个月的患者按3:1:1随机分配至低强度冲击波治疗组、假治疗组和索利那新10毫克/日组。主要终点为3个月随访时膀胱过度活动症症状评分(OABSS)较基线的降低百分比。结果显示低强度冲击波治疗组OABSS降低百分比显著高于假治疗组(-55%对-11%),与索利那新10毫克组相当(-55%对-60%),且耐受性更好。
要点
- 低强度冲击波治疗组3个月OABSS较基线降低55%,假治疗组降低11%。
- 低强度冲击波治疗组OABSS降低55%,索利那新10毫克组降低60%,两组相当。
- 索利那新10毫克组73%患者出现困扰性不良反应,11.5%停药。
核心结论
- 低强度冲击波治疗可改善经尿道手术治疗良性前列腺梗阻后持续储尿症状并提升生活质量,与索利那新相比疗效相当且耐受性更好。
研究设计与样本
- 随机对照试验,2020年7月至2022年7月纳入137例经尿道手术治疗良性前列腺梗阻后持续储尿症状至少三个月、24小时尿急发作≥1次且日间排尿频率≥8次的患者。
- 患者按3:1:1比例随机分配至低强度冲击波治疗组、假治疗组和索利那新10毫克/日组。
- 主要终点为3个月随访时OABSS较基线的降低百分比。
主要发现
- 3个月随访时OABSS较基线降低百分比:低强度冲击波治疗组-55%对假治疗组-11%,差异显著。
- 3个月随访时OABSS较基线降低百分比:低强度冲击波治疗组-55%对索利那新10毫克组-60%,两组相当。
- 低强度冲击波治疗在3天排尿日记参数和生活质量评分方面的改善与索利那新10毫克组相当,6个月随访时两组仍相当。
- 除操作过程中可耐受的疼痛外,未观察到与低强度冲击波治疗相关的不良反应。
- 索利那新10毫克组73%患者出现困扰性不良反应,停药率11.5%。
临床怎么用
- 作者认为低强度冲击波治疗可改善经尿道手术治疗良性前列腺梗阻后持续储尿症状并提升生活质量,与索利那新相比疗效相当且耐受性更好。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Low-intensity shockwave therapy (Li-SWT) can improve bladder function through enhancement of angiogenesis and nerve regeneration and suppression of inflammation and overactivity. In this trial, we aimed to evaluate the efficacy of Li-SWT on persistent storage symptoms after transurethral surgery (TUS) for benign prostatic obstruction (BPO). METHODS: Between July 2020 and July 2022, 137 patients with persistent storage symptoms; urgency episodes/24 h ≥ 1 and daytime frequency ≥8, for at least three months after TUS for BPO were randomly allocated to Li-SWT versus sham versus solifenacin 10 mg/day in 3:1:1 ratio. The primary end point was the percent reduction from baseline in overactive bladder symptom score (OABSS) at 3-month follow-up. The changes in 3-day voiding diary parameters, quality of life (QoL) score, peak flow rate and residual urine at 3 and 6-month follow-up were compared. Treatment-related adverse effects were also evaluated. RESULTS: Baseline data were comparable between groups. The percent reduction from baseline in OABSS at 3-month follow-up was significantly higher in Li-SWT compared to sham (-55% versus -11%), and it was comparable between Li-SWT and solifenacin-10 (-55% versus -60%). Li-SWT achieved significant improvement like solifenacin-10 in 3-day voiding diary parameters and QoL score at 3-month follow-up. This improvement remained comparable between Li-SWT and solifenacin-10 at 6-month follow-up. No adverse effects related to Li-SWT were noted apart from tolerable pain during the procedure. Solifenacin-10 was associated with bothersome adverse effects in 73% of the patients with 11.5% discontinuation rate. CONCLUSIONS: Li-SWT ameliorates persistent storage symptoms and promotes QoL after TUS for BPO, with comparable efficacy and better tolerance compared to solifenacin.
引用
- Hegazy M, Sheir KZ, Gaballah MA, et al. A randomized controlled trial evaluating low-intensity shockwave therapy for treatment of persistent storage symptoms following transurethral surgery for benign prostatic obstruction. Prostate Cancer Prostatic Dis. 2024. PMID: 38553627. doi:10.1038/s41391-024-00820-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。